Cellectar Biosciences Inc (CLRB)

[Crusader]

Stock Report: CLRB GOING TO $7.44 PPS

"...using strategic partnerships"!!!

http://finance.yahoo.com/news/seethruequity-initiates-coverage-cellectar-biosciences-130000249.html

THEY CONCLUDED AS I DID:

..."Cellectar's lead candidate using PDC is CLR-131, a Phase 1 candidate for the treatment of multiple myeloma.
Cellectar intends for PDC to serve as a platform technology, which can be used to address many cancer types. We would expect the company to pursue a strategy in which it demonstrates the effectiveness of the platform with initial candidates covering a diverse group of payloads. Then we would expect Cellectar to advance new indications though strategic partnerships with larger pharmaceutical companies better equipped to fully fund new drug development. In our view, Cellectar is a speculative company in the biotechnology sector with the potential to develop and commercialize an impactful new cancer targeting and payload delivery technology in the large and growing market for oncology therapeutics," commented Ajay Tandon, CEO of SeeThruEquity. "We initiate coverage on Cellectar with a price target of $7.44.":


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123735723

Expect press releases, starting THIS week.